DuPont de Nemours, Inc. · NYSE:DD
DuPont de Nemours — DuPont — Q4 2013 Earnings Presentation
30 slides from DuPont de Nemours's earnings presentation, Jan 28, 2014
Slide 1: DuPont 4Q 2013 Earnings Conference Call
DuPont 4Q 2013 Earnings Conference Call January 28, 2014 1
Slide 2: Regulation G, Forward Looking Statements, Developing Markets
Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this data is meaningful to investors because it provides insight with respect to ongoing operating results of the company and
Slide 3: 4Q and FY 2013 Financial Highlights
4Q and FY 2013 Financial Highlights* $ in millions, except EPS 4Q13 vs. 4Q12 FY13 vs. FY12 EPS Operating earnings** $0.59 195% $3.88 3% GAAP earnings $0.19 $3.04 4Q13 vs. 4Q12 FY13 vs. FY12 Consolidated Net Sales $7,747 6% $35,734 3% Volume 9% 5% Local Prices (2)% (1)% Currency Impact (1)% (1)% Segm
Slide 4: Global Sales – Regional Highlights
Global Sales – Regional Highlights 4Q 2013 Sales by Region 4Q 2013 Sales YOY % CHG Region % Latin America U.S. & Canada 17% 34% Worldwide 6 U.S. & Canada 4 Developed EMEA 8 Developed Asia 11% Developing Developed Asia (3) EMEA 6% Developing Markets 9 Developing Developed Asia EMEA Developing Asia 6
Slide 5: 4Q 2013 Segment Operating Earnings Variance
4Q 2013 Segment Operating Earnings* Variance $22 ($7) ($1) ($5) $23 $50 $76 $165 $939* $616* 4Q 2012 Ag S&P E&C N&H Perf Mtls Perf Chem IB Pharma & 4Q 2013 Other Agriculture fourth quarter profit due to strong insecticides & earlier seed shipments Key Safety & Protection, Electronics & Communica
Slide 6: 4Q 2013 Operating EPS Variance
4Q 2013 Operating EPS* Variance $0.03 ($0.01) $0.11 $0.26 $ 0.59* $0.20* 4Q 2012 Segment results Tax rate change Corp exp & interest EGL 4Q 2013 Strong segment performance reflects volume growth in all segments Key Segment results include a $.04 negative currency impact Takeaways Lower base ta
Slide 7: Balance Sheet and Cash
Balance Sheet and Cash December 31, 2013 Free Cash Flow Free Cash Flow* • Changes in Agriculture working capital 2012 2013 4.0 • Lower Performance Chemicals earnings • Absence of Performance Coatings segment 3.0 $ Billions • Capex spend $1.9B, up from $1.8B in 2012 2.0 Strong Balance Sheet 1.0 • $3.
Slide 8: 2014 Assumptions
2014 Assumptions Key Market Summary Macroeconomic Outlook • Global Ag economy remains healthy • Global GDP up 3% vs. about 2% in 2013 ⁻ Commodity prices favor soybeans over corn • Industrial Production up nearly 4% ⁻ Expect lower corn planted area ⁻ Europe and Japan recover from recessions, • Global
Slide 9: 2014 Expectations and Outlook
2014 Expectations and Outlook • Revenue up 4% to about $37B, including about a 2% decline for portfolio changes • Operating EPS* earnings range of $4.20 - $4.45 per share – Includes $2B share buyback • Base tax rate ~22% • Capital Expenditures ~$1.9B • Minimal Pharma income, included in Other in 201
Slide 10: $5 Billion Share Repurchase Program
$5 Billion Share Repurchase Program • Expect to complete $2B in 2014 • Repurchases begin in Q1 using existing cash • Anticipate reduction in diluted share count at year end Assumes: • Current share price • Estimated dilution • Program has no time limit • Financial discipline & desired balance sheet
Slide 11: Agriculture
Agriculture Pioneer, Crop Protection 4Q Sales * 4Q Comments 2.0 2013 sales +13%, operating earnings +16% 1.5 4Q sales +18%, operating earnings turn positive at $88 million $ in Billions Strong insecticide sales in Latin America 1.0 Earlier timing of seed shipments 0.5 Partially offset by n
Slide 12: Electronics & Communications
Electronics & Communications 4Q Sales * 1.0 4Q Comments Operating earnings increased $50 million to $93 million 0.8 $ in Billions Significant volume gains, mainly from demand 0.6 improvement and share gains in photovoltaic markets 0.4 Lower selling prices, largely from the pass-through of lowe
Slide 13: Industrial Biosciences
Industrial Biosciences 4Q Sales * 4Q Comments 0.4 Sales up 9% on higher volumes 0.3 Continued strong demand for Sorona® polymer $ in Billions for carpeting and apparel volumes 0.2 Increased enzyme demand for ethanol production 0.1 Operating earnings were essentially flat as higher 0.0 sales
Slide 14: Nutrition & Health
Nutrition & Health 4Q Sales * 4Q Comments 1.0 Operating earnings of $81 million increased $23 million 0.8 Sales growth driven by pricing gains and increased $ in Billions 0.6 demand in specialty proteins, probiotics and cultures 0.4 Operating margin improved more than two points as 0.2 pricing
Slide 15: Performance Chemicals
Performance Chemicals Titanium Technologies (DTT), Chemicals & Fluoroproducts (DC&F) 4Q Sales * 4Q Comments Sales up slightly as higher volumes for Ti02 and 2.0 fluoroproducts were partially offset by lower prices $ in Billions 1.5 Ti02 volume up 18%, strong volume growth in EMEA, China 1.0 Fo
Slide 16: Performance Materials
Performance Materials Performance Polymers (DPP), Packaging & Industrial Polymers (P&IP) 4Q Sales * 4Q Comments 2.0 Sales up 3% with higher volumes partially offset by lower 1.6 prices $ in Billions 1.2 Automotive, construction, and packaging market demand improving 0.8 Polymer demand in China
Slide 17: Safety & Protection
Safety & Protection Protection Technologies (DPT), Building Innovations (BI), Sustainable Solutions (DSS) 4Q Sales * 4Q Comments 1.2 Sales up 1% on higher volumes 1.0 Higher volume primarily reflects increased $ in Billions 0.8 industrial market demand 0.6 0.4 Productivity improvements and bet
Slide 18: Copyright © 2014 DuPont. All rights reserved.
Copyright © 2014 DuPont. All rights reserved. The DuPont Oval Logo, DuPontTM, The miracles of scienceTM, and all products denoted with ® or M are trademarks or registered trademarks of E. I. du Pont de Nemours and Company. 18
Slide 19: DuPont Segment Commentary: Agriculture
Fourth Quarter Earnings DuPont Segment Commentary 2013 This data should be read in conjunction with the Company’s fourth quarter earnings news release dated January 28, 2014 and DuPont’s 4Q 2013 Earnings Conference Call presentation materials and reconciliations of Non-GAAP measures posted on the In
Slide 20: DuPont Segment Commentary
Fourth Quarter Earnings DuPont Segment Commentary 2013 Fourth quarter sales of $1.8 billion increased 18 percent driven by volume gains of 14 percent and the benefit of increased ownership in Pannar Seed (Pty) Ltd., despite a significant currency headwind primarily from the Real which offset pricing
Slide 21: DuPont Segment Commentary
Fourth Quarter Earnings DuPont Segment Commentary 2013 For the first half of 2014, we anticipate modest increases in both sales and operating earnings with growth rates negatively impacted by the previously mentioned timing change of about $100 million in operating earnings. We expect operating marg
Slide 22: DuPont Segment Commentary: Electronics & Communications
Fourth Quarter Earnings DuPont Segment Commentary 2013 Electronics & Communications 4Q Sales * 1.0 4Q Comments Operating earnings increased $50 million to $93 million 0.8 $ in Billions Significant volume gains, mainly from demand 0.6 improvement and share gains in photovoltaic markets 0.4 Lowe
Slide 23: DuPont Segment Commentary
Fourth Quarter Earnings DuPont Segment Commentary 2013 For the first quarter, we anticipate operating earnings to be up about 50 percent. Sales are expected to be essentially flat as continued volume gains, driven by relatively strong photovoltaic demand, will be largely offset by lower selling pric
Slide 24: DuPont Segment Commentary: Industrial Biosciences
Fourth Quarter Earnings DuPont Segment Commentary 2013 Industrial Biosciences 4Q Sales * 4Q Comments 0.4 Sales up 9% on higher volumes 0.3 Continued strong demand for Sorona® polymer $ in Billions for carpeting and apparel volumes 0.2 Increased enzyme demand for ethanol production 0.1 Operat
Slide 25: DuPont Segment Commentary: Nutrition & Health
Fourth Quarter Earnings DuPont Segment Commentary 2013 Nutrition & Health 4Q Sales * 4Q Comments 1.0 Operating earnings of $81 million increased $23 million 0.8 Sales growth driven by pricing gains and increased $ in Billions 0.6 demand in specialty proteins, probiotics and cultures 0.4 Operat
Slide 26: DuPont Segment Commentary: Performance Chemicals
Fourth Quarter Earnings DuPont Segment Commentary 2013 Performance Chemicals Titanium Technologies (DTT), Chemicals & Fluoroproducts (DC&F) 4Q Sales * 4Q Comments Sales up slightly as higher volumes for Ti02 and 2.0 fluoroproducts were partially offset by lower prices $ in Billions 1.5 Ti02 volu
Slide 27: DuPont Segment Commentary
Fourth Quarter Earnings DuPont Segment Commentary 2013 Although fourth quarter operating earnings were down 3%, this reflects lower year over year declines versus prior quarters when earnings declined 56% in the first half and 38% in the third quarter. In the first quarter, we anticipate sales will
Slide 28: DuPont Segment Commentary: Performance Materials
Fourth Quarter Earnings DuPont Segment Commentary 2013 Performance Materials Performance Polymers (DPP), Packaging & Industrial Polymers (P&IP) 4Q Sales * 4Q Comments 2.0 Sales up 3% with higher volumes partially offset by lower 1.6 prices $ in Billions 1.2 Automotive, construction, and packagin
Slide 29: DuPont Segment Commentary: Safety & Protection
Fourth Quarter Earnings DuPont Segment Commentary 2013 Safety & Protection Protection Technologies (DPT), Building Innovations (BI), Sustainable Solutions (DSS) 4Q Sales * 4Q Comments 1.2 Sales up 1% on higher volumes 1.0 Higher volume primarily reflects increased $ in Billions 0.8 industrial ma
Slide 30: Use of Non-GAAP Measures
Fourth Quarter Earnings DuPont Segment Commentary 2013 Use of Non-GAAP Measures This Commentary includes information that does not conform to generally accepted accounting principles (GAAP). Management believes that analysis of this data is meaningful to investors because they provide insight with r